Navigation Links
InCode BioPharmaceutics Appoints New President and CEO
Date:11/20/2008

SAN FRANCISCO, Nov. 20 /PRNewswire/ -- InCode BioPharmaceutics, Inc., an emerging company in complement depletion, announced that it has appointed Kevin L. Stark, Ph.D. as President and Chief Executive Officer, effective immediately. Dr. Stark has more than 19 years experience as a biopharmaceutical researcher and executive, most recently as an Executive Director at Amgen, and Chief Operating Officer at iZumi Bio, Inc. His latest responsibilities included strategic operations within R&D, integration of mergers and acquisitions, licensing, and business development.

"We are very pleased to appoint Kevin Stark as our CEO," said Jay Lichter, Ph.D., Chairman of the Board. "We believe his experience, which spans basic research to executive management, will be instrumental as the company advances into drug development and seeks potential partnerships."

Dr. Stark received a Ph.D. in Pharmacology from the University of Washington, and a B.S. in Zoology from Colorado State University.

InCode also announced that William St. John has resigned as President and Chief Executive Officer, and will remain on the Board of Directors.

"We are very grateful to Bill for his vision in recognizing the promise of complement depletion in human disease, and his role in building the company to this point," said Carl-Wilhelm Vogel, MD, Ph.D., Founder and Board Member, from the Cancer Research Center of Hawaii.

In conjunction with this transition, the company will shift operations from the San Francisco, CA location to the Thousand Oaks, CA area.

About InCode

InCode's novel approach is focused on the selective interruption of the complement cascade. Activation of the complement cascade has been implicated in the pathogenesis of many inflammatory diseases, including rheumatoid arthritis, asthma, ischemia-reperfusion injury and age-related macular degene
'/>"/>

SOURCE InCode BioPharmaceutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
2. GeneNews appoints Canadian Colorectal Cancer Advisory Board
3. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
4. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
5. Accumetrics Appoints John J. Young, MD Chief Medical Officer
6. Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
7. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
8. Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
9. NutraCea Appoints New Chief Financial Officer
10. Cardiac Science Appoints Dave Marver as Chief Operating Officer
11. Nutrition 21 Appoints Pam McWilliams, Vice President - General Manager of Direct Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... famous for a number of breakthroughs, which altered the ... a paper, which laid the foundation of computer science, ... He next played a pivotal role in the Second ... military codes, enabling the Allies to defeat the Nazis ... he turned his attention to artificial intelligence and proposed ...
(Date:7/31/2014)... , July 31, 2014 The ... today with $25,000 to fund a translational research ... in 2011, the gift was presented at the ... Annual Meeting in Colorado Springs, CO. ... in neurointerventional approaches to neurovascular conditions, SNIS formed ...
(Date:7/31/2014)... North Shore Towers, a luxury co-op community based just ... of the nation’s leading combined heating and power (CHP) systems ... CHP system. The original CHP system had been maintained since ... life of the plant, GI Energy was contracted to replace ... equipment, while maintaining continuous operation of the entire complex. ...
(Date:7/31/2014)... DIEGO, July 31, 2014 Senomyx ... leading company using proprietary taste science technologies to ... the food, beverage, and ingredient supply industries, today ...  The Company ended the second quarter with $33.6 ... "During the past quarter Senomyx achieved ...
Breaking Biology Technology:A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 3SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16
... Nov. 21, 2011 WaferGen Biosystems, Inc. (OTCBB:WGBS), an ... the three and nine months ended September 30, 2011 ... adoption of its SmartChip System. "During the ... strategy to address the rapidly changing needs of the ...
... Phase I Single Dose Study Data ... Convergence Pharmaceuticals Limited ("Convergence"), the company focused ... medicines, today announces that the multiple ascending dose Phase ... channel blocker CNV2197944, for the treatment of chronic pain ...
... Japan, November 18, 2011 - A research group from ... and Fujitsu Limited today announced that research results obtained ... Bell Prize, Peak-Performance at SC11, the International Conference for ... in Seattle, on November 17 (US Pacific Standard Time). ...
Cached Biology Technology:WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 2WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 3WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 4WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 5WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 6WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 7WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 8Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 2Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 3Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 4'K computer' research results awarded ACM Gordon Bell Prize 2
(Date:8/1/2014)... Modern humans appear in the fossil record about 200,000 ... ago that making art and advanced tools became widespread. ... the journal Current Anthropology finds that human ... testosterone levels at around the same time that culture ... innovation, making art and rapid cultural exchange probably came ...
(Date:8/1/2014)... examining a taxonomically confused group of marine mammals ... the Australian humpback dolphin, Sousa sahulensis , ... Enterprises. , The study describing the newly ... long systematic examination of all available historical records, ... widespread group of coastal cetaceans ranging from the ...
(Date:8/1/2014)... key component of phloem, the conductive tissue through which ... molecules. Elongated cylindrical cells are capped at one end ... sieve tubes which in turn form a network throughout ... very special cells which play an important role in ... known about their differentiation," says Professor Yk Helariutta from ...
Breaking Biology News(10 mins):Society bloomed with gentler personalities and more feminine faces 2Scientists name new species of cetacean: The Australian humpback dolphin 2Scientists name new species of cetacean: The Australian humpback dolphin 3Developmental regulation of important plant phloem components discovered 2
... 28, 2013Scientists at The Scripps Research Institute (TSRI) have determined ... the hepatitis C virus, which the virus uses to infect ... this protein and should greatly speed efforts to make an ... the November 29, 2013 issue of the journal Science ...
... have developed a series of techniques to create a ... the alcohols and amines used in the drug and ... safer and more economical and environmentally friendly than traditional ... extensive supply of iron the fifth most abundant ...
... 2013) An international team of scientists, including researchers at Columbia ... that common malaria parasites require for survival at each stage ... a new approach to combating malaria, one of the world,s ... edition of the journal Nature . "Perhaps ...
Cached Biology News:Scripps Research Institute scientists achieve most detailed picture ever of key part of hepatitis C 2Scripps Research Institute scientists achieve most detailed picture ever of key part of hepatitis C 3Iron-based process promises greener, cheaper and safer drug and perfume production 2Study finds new vulnerability in malaria parasite 2
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
Mouse monoclonal [IFR0104] to Salmonella enteriditis ( Abpromise for all tested applications)....
All serum is collected from adult animals aged 6 months or older. Certified U.S. orgin. Pricing: $35/unit for 1 - 10 units...
Biology Products: